It was noteworthy that both sCD163 and sMR levels were significantly decreased by a four-week rifaximin treatment, and that these decreases showed highly positive correlations with improvements in endotoxemia, indicating that rifaximin might recover impaired intestinal permeability in cirrhotic patients. Here, CD163 is linked to serum lipopolysaccharide activity.